Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-infectives - Emergent BioSolutions

Drug Profile

Research programme: anti-infectives - Emergent BioSolutions

Alternative Names: 2-pyridone based topoisomerase inhibitors (EV-035); EBX 205; EV 035 series - Emergent BioSolutions; EV-021; EV-035; EV-035a; EV-035b; EV-035c; EV-075; EV-086; GC-0146; GC-061; GC-063; GC-072

Latest Information Update: 19 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolva Biotech
  • Developer Emergent BioSolutions; United States Army Research Laboratory
  • Class Antibacterials; Pyridones; Small molecules
  • Mechanism of Action Immunomodulators; Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anthrax; Burkholderia infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Discontinued Ebola virus infections; Escherichia coli infections; Influenza virus infections; Mycoses

Most Recent Events

  • 14 Jul 2018 Antimicrobial data from in vitro studies in Public health threats presented at ASM Microbe (ASMM - 2018)
  • 04 Jun 2018 Preclinical development in Bacterial infections, Methicillin-resistant Staphylococcus aureus infections, Anthrax and Burkholderia infections is ongoing in USA (PO) (Emergent Biosciences pipeline, June 2018)
  • 04 Jun 2018 Discontinued - Preclinical for Escherichia coli infections in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top